Antithrombotics for secondary prevention of noncardioembolic ischaemic stroke

Nature Reviews Neurology

Volumn 8, Issue 4, 2012, Pages 223-235

  Warden, Bruce A ^a   Willman, Alana M ^b   Williams, Craig D ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CLOPIDOGREL; DIPYRIDAMOLE; PLACEBO; PRASUGREL; RIVAROXABAN; SULFINPYRAZONE; SULOCTIDIL; TERUTROBAN; THIENOPYRIDINE DERIVATIVE; TICAGRELOR; TICLOPIDINE; WARFARIN;

ANTICOAGULATION; ATHEROSCLEROTIC PLAQUE; BLEEDING; BRAIN ISCHEMIA; DRUG CHOICE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEMOSTASIS; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; MONOTHERAPY; NEUTROPENIA; NONCARDIOEMBOLIC ISCHEMIC STROKE; OPTIMAL DRUG DOSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; TRANSIENT ISCHEMIC ATTACK;

BRAIN ISCHEMIA; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; FIBRINOLYTIC AGENTS; HUMANS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; SECONDARY PREVENTION; STROKE;

EID: 84859566457     PISSN: 17594758     EISSN: 17594766     Source Type: Journal    
DOI: 10.1038/nrneurol.2012.33     Document Type: Review

References (67)

1. Lloyd-Jones, D. et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association. Circulation 121, e46-e215 (2010).
2. European Stroke Initiative Executive Committee & EUSI Writing Committee. European Stroke Initiative recommendations for stroke management-update 2003. Cerebrovasc. Dis. 16, 311-337 (2003).
3. Furie, K. L. et al. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 42, 227-276 (2011).
4. Singer, D. E. et al. Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (Suppl. 6), 546S-592S (2008).
5. Halkes, P. H., van Gijn, J., Kappelle, L. J., Koudstaal, P. J. & Algra, A. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 367, 1665-1673 (2006).
6. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324, 71-86 (2002).
7. Hanley. D. et al. Determining the appropriateness of selected surgical and medical management options in recurrent stroke prevention: a guideline for primary care physicians from the National Stroke Association work group on recurrent stroke prevention. J. Stroke Cerebrovasc. Dis. 13, 196-207 (2004).
8. European Stroke Organisation (ESO) Executive Committee & ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc. Dis. 25, 457-507 (2008).
9. Adams, R. J. et al. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 39, 1647-1652 (2008).
10. Albers, G. W., Amarenco, P., Easton, J. D., Sacco, R. L. & Teal, P. Antithrombotic and thrombolytic therapy for ischemic stroke: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133 (Suppl. 6), 630S-669S (2008).
11. Sacco, R. L. et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Stroke 37, 577-617 (2006).
12. Davi, G. & Patrono, C. Platelet activation and atherothrombosis. N. Engl. J. Med. 357, 2482-2494 (2007).
13. [No authors listed] Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 308, 81-106 (1994).
14. [No authors listed] Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration. Br. Med. J. (Clin. Res. Ed.) 296, 320-331 (1988).
15. Baigent, C. et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 373, 1849-1860 (2009).
16. Quick, A. J. Salicylates and bleeding: the aspirin tolerance test. Am. J. Med. Sci. 252, 265-269 (1966).
17. Fields, W. S., Lemak, N. A., Frankowski, R. F. & Hardy, R. J. Controlled trial of aspirin in cerebral ischemia. Stroke 8, 301-314 (1977).
18. Chimowitz, M. I. et al. Comparison of warfarin and aspirin for symptomatic intracranial arterial stenosis. N. Engl. J. Med. 352, 1305-1316 (2005).
19. Mohr, J. P. et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N. Engl. J. Med. 345, 1444-1451 (2001).
20. Halkes, P. H., van Gijn, J., Kappelle, L. J., Koudstaal, P. J. & Algra, A. Medium intensity oral anticoagulants versus aspirin after cerebral ischaemia of arterial origin (ESPRIT): a randomised controlled trial. Lancet Neurol. 6, 115-124 (2007).
21. Wolf, P. A. et al. Preventing ischemic stroke in patients with prior stroke and transient ischemic attack: a statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 30, 1991-1994 (1999).
22. [No authors listed] European Stroke Initiative recommendations for stroke management. European Stroke Council, European Neurological Society and European Federation of Neurological Societies. Cerebrovasc. Dis. 10, 335-351 (2000).
23. Johnson, E. S. et al. A metaregression analysis of the dose-response effect of aspirin on stroke. Arch. Intern. Med. 159, 1248-1253 (1999).
24. Algra, A. & van Gijn, J. Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J. Neurol. Neurosurg. Psychiatry 60, 197-199 (1996).
25. Farrell, B., Godwin, J., Richards, S. & Warlow, C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J. Neurol. Neurosurg. Psychiatry 54, 1044-1054 (1991).
26. [No authors listed] A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. The Dutch TIA Trial Study Group. N. Engl. J. Med. 325, 1261-1266 (1991).
27. De Schryver, E. L., Algra, A. & van Gijn, J. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database of Systematic Reviews, Issue 3. Art. No.: CD001820. http://dx.doi.org/10.1002/14651858.CD001820.pub3 (2007).
28. Guiraud-Chaumeil, B. et al. Prevention of recurrences of cerebral ischemic vascular accidents by platelet antiaggregants. Results of a 3-year controlled therapeutic trial [French]. Rev. Neurol. (Paris) 138, 367-385 (1982).
29. Bousser, M. G. et al. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia. Stroke 14, 5-14 (1983).
30. Diener, H. C. et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J. Neurol. Sci. 143, 1-13 (1996).
31. [No authors listed] The European Stroke Prevention Study (ESPS). Principal end-points. The ESPS Group. Lancet 330, 1351-1354 (1987).
32. [No authors listed] United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. UK-TIA Study Group. Br. Med. J. (Clin. Res. Ed.) 296, 316-320 (1988).
33. Albers, G. W., Hart, R. G., Lutsep, H. L., Newell, D. W. & Sacco, R. L. AHA Scientific Statement. Supplement to the guidelines for the management of transient ischemic attacks: a statement from the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association. Stroke 30, 2502-2511 (1999).
34. Chaturvedi, S. Acetylsalicylic acid + extended-release dipyridamole combination therapy for secondary stroke prevention. Clin. Ther. 30, 1196-1205 (2008).
35. Verro, P., Gorelick, P. B. & Nguyen, D. Aspirin plus dipyridamole versus aspirin for prevention of vascular events after stroke or TIA: a meta-analysis. Stroke 39, 1358-1363 (2008).
36. Sacco, R. L. et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N. Engl. J. Med. 359, 1238-1251 (2008).
37. Roden, D. M. & Stein, C. M. Clopidogrel and the concept of high-risk pharmacokinetics. Circulation 119, 2127-2130 (2009).
38. Sudlow, C. L., Mason, G., Maurice, J. B., Wedderburn, C. J. & Hankey, G. J. Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database of Systematic Reviews, Issue 4. Art. No.: CD001246. http://dx.doi.org/10.1002/ 14651858.CD001246.pub2 (2009).
39. Gent, M. et al. The Canadian American Ticlopidine Study (CATS) in thromboembolic stroke. Lancet 1, 1215-1220 (1989).
40. Hass, W. K. et al. A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group. N. Engl. J. Med. 321, 501-507 (1989).
41. Quinn, M. J. & Fitzgerald, D. J. Ticlopidine and clopidogrel. Circulation 100, 1667-1672 (1999).
42. Juurlink, D. N. Proton pump inhibitors and clopidogrel: putting the interaction in perspective. Circulation 120, 2310-2312 (2009).
43. Storey, R. F. Clopidogrel in acute coronary syndrome: to genotype or not? Lancet 373, 276-278 (2009).
44. Pare, G. et al. Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. N. Engl. J. Med. 363, 1704-1714 (2010).
45. Mega, J. L. et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360, 354-362 (2009).
46. [No authors listed] A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 348, 1329-1339 (1996).
47. Yusuf, S. et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345, 494-502 (2001).
48. Steinhubl, S. R. et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 288, 2411-2420 (2002).
49. Diener, H. C. et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 364, 331-337 (2004).
50. Bhatt, D. L. et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N. Engl. J. Med. 354, 1706-1717 (2006).
51. Hankey, G. J. et al. Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: a prespecified substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial. Stroke 41, 1679-1683 (2010).
52. Bhatt, D. L. et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J. Am. Coll. Cardiol. 49, 1982-1988 (2007).
53. Benavente, O. R. et al. The Secondary Prevention of Small Subcortical Strokes (SPS3) study. Int. J. Stroke 6, 164-175 (2011).
54. European Stroke Organisation (ESO) Executive Committee & ESO Writing Committee. Guidelines for the management of ischemic stroke and transient ischemic attack. Cerebrovasc. Dis. 25, 457-507 (2008).
55. Thijs, V., Lemmens, R. & Fieuws, S. Network meta-analysis: simultaneous meta-analysis of common antiplatelet regimens after transient ischaemic attack or stroke. Eur. Heart J. 29, 1086-1092 (2008).
56. O'Donnell, M. J., Hankey, G. J & Eikelboom, J. W. Antiplatelet therapy for secondary prevention of noncardioembolic ischemic stroke: a critical review. Stroke 39, 1638-1646 (2008).
57. Wiviott, S. D. et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357, 2001-2015 (2007).
58. Davies, M. J. Pathology of arterial thrombosis. Br. Med. Bull. 50, 789-802 (1994).
59. Schafer, A. I. Antiplatelet therapy. Am. J. Med. 101, 199-209 (1996).
60. [No authors listed] A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. Ann. Neurol. 42, 857-865 (1997).
61. Clarke, R. J., Mayo, G., Price, P. & FitzGerald, G. A. Suppression of thromboxane A2 but not of systemic prostacyclin by controlled-release aspirin. N. Engl. J. Med. 325, 1137-1141 (1991).
62. Mega, J. L. et al. Rivaroxaban in patients with a recent acute coronary syndrome. N. Engl. J. Med. 366, 9-19 (2012).
63. Chang, Y. J., Ryu, S. J. & Lee, T. H. Dose titration to reduce dipyridamole-related headache. Cerebrovasc. Dis. 22, 258-262 (2006).
64. Lindgren, A., Husted, S., Staaf, G. & Ziegler, B. Dipyridamole and headache-a pilot study of initial dose titration. J. Neurol. Sci. 223, 179-184 (2004).
65. Williams, C. D, Cherala, G. & Serebruany, V. Application of platelet function testing to the bedside. Thromb. Haemost. 103, 29-33 (2010).
66. Price, M. J. et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305, 1097-1105 (2011).
67. Mega, J. L. et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA 306, 2221-2228 (2011).